MBQ Pharma announces the First-in-Human Dose of MBQ-167 for Advanced Breast Cancer in a Phase 1 Clinical Trial in Puerto Rico with the dual targeted Rac/Cdc42 inhibitor
MBQ Pharma announces a significant milestone in its journey; they have dosed the first participant in Phase 1 clinical trial of MBQ-167.
FDA Acceptance of IND 148376 for MBQ-167 Phase 1 Study
Study May Proceed
